Sonelokimab Antibody is a research-grade biosimilar monoclonal antibody targeting CTLA-8. Format: VH-VH'-VH (humanized host). Reactivity: Human. Supplied as a liquid in 30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.